Naringin, the major grapefruit flavonoid, specifically affects atherosclerosis development in diet-induced hypercholesterolemia in mice

Journal of Nutritional Biochemistry

Volumn 23, Issue 5, 2012, Pages 469-477

  Chanet, Audrey ^a,b   Milenkovic, Dragan ^a,b   Deval, Christiane ^a,b   Potier, Mylène ^c   Constans, Joël ^c   Mazur, Andrzej ^a,b   Bennetau Pelissero, Catherine ^c   Morand, Christine ^a,b   Bérard, Annie M ^c  

^a CRNH AUVERGNE   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Atherosclerosis; Flavonoid; High fat high cholesterol diet; Hypercholesterolemic mouse models; Naringin; Transcriptomic

Indexed keywords

AURANTIIN; CHOLESTEROL;

ACTIN FILAMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CELL DIVISION; CELL PROLIFERATION; CHOLESTEROL DIET; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; SMOOTH MUSCLE FIBER; TRANSCRIPTOMICS;

ANIMALS; ATHEROSCLEROSIS; CITRUS PARADISI; DIET, ATHEROGENIC; ENDOTHELIAL CELLS; FLAVANONES; HYPERCHOLESTEROLEMIA; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MONOCYTES; MYOCYTES, SMOOTH MUSCLE;

CITRUS X PARADISI; MUS;

EID: 84859811000     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.02.001     Document Type: Article

References (50)

1. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
2. Dauchet L., Ferrieres J., Arveiler D., Yarnell J.W., Gey F., Ducimetiere P., et al. Frequency of fruit and vegetable consumption and coronary heart disease in France and Northern Ireland: the PRIME study. Br J Nutr 2004, 92:963-972.
3. Hertog M.G., Feskens E.J., Hollman P.C., Katan M.B., Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993, 342:1007-1011.
4. Mink P.J., Scrafford C.G., Barraj L.M., Harnack L., Hong C.P., Nettleton J.A., et al. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr 2007, 85:895-909.
5. Manach C., Scalbert A., Morand C., Remesy C., Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004, 79:727-747.
6. Ovaskainen M.L., Torronen R., Koponen J.M., Sinkko H., Hellstrom J., Reinivuo H., et al. Dietary intake and major food sources of polyphenols in Finnish adults. J Nutr 2008, 138:562-566.
7. Lee C.H., Jeong T.S., Choi Y.K., Hyun B.H., Oh G.T., Kim E.H., et al. Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits. Biochem Biophys Res Commun 2001, 284:681-688.
8. Choe S.C., Kim H.S., Jeong T.S., Bok S.H., Park Y.B. Naringin has an antiatherogenic effect with the inhibition of intercellular adhesion molecule-1 in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 2001, 38:947-955.
9. Mulvihill E.E., Assini J.M., Sutherland B.G., DiMattia A.S., Khami M., Koppes J.B., et al. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol 2010, 30:742-748.
10. Jung U.J., Lee M.K., Park Y.B., Kang M.A., Choi M.S. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int J Biochem Cell Biol 2006, 38:1134-1145.
11. Mulvihill E.E., Allister E.M., Sutherland B.G., Telford D.E., Sawyez C.G., Edwards J.Y., et al. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes 2009, 58:2198-2210.
12. Huong D.T., Takahashi Y., Ide T. Activity and mRNA levels of enzymes involved in hepatic fatty acid oxidation in mice fed citrus flavonoids. Nutrition 2006, 22:546-552.
13. Wilcox L.J., Borradaile N.M., de Dreu L.E., Huff M.W. Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. J Lipid Res 2001, 42:725-734.
14. Borradaile N.M., de Dreu L.E., Barrett P.H., Behrsin C.D., Huff M.W. Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation. Biochemistry 2003, 42:1283-1291.
15. Allister E.M., Mulvihill E.E., Barrett P.H., Edwards J.Y., Carter L.P., Huff M.W. Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor. J Lipid Res 2008, 49:2218-2229.
16. Borradaile N.M., de Dreu L.E., Huff M.W. Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation. Diabetes 2003, 52:2554-2561.
17. Vafeiadou K., Vauzour D., Lee H.Y., Rodriguez-Mateos A., Williams R.J., Spencer J.P. The citrus flavanone naringenin inhibits inflammatory signalling in glial cells and protects against neuroinflammatory injury. Arch Biochem Biophys 2009, 484:100-109.
18. Garcia-Conesa M.T., Tribolo S., Guyot S., Tomas-Barberan F.A., Kroon P.A. Oligomeric procyanidins inhibit cell migration and modulate the expression of migration and proliferation associated genes in human umbilical vascular endothelial cells. Mol Nutr Food Res 2009, 53:266-276.
19. Stangl V., Dreger H., Stangl K., Lorenz M. Molecular targets of tea polyphenols in the cardiovascular system. Cardiovasc Res 2007, 73:348-358.
20. Paigen B., Morrow A., Brandon C., Mitchell D., Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985, 57:65-73.
21. Li Y., Gilbert T.R., Matsumoto A.H., Shi W. Effect of aging on fatty streak formation in a diet-induced mouse model of atherosclerosis. J Vasc Res 2008, 45:205-210.
22. Paigen B., Morrow A., Holmes P.A., Mitchell D., Williams R.A. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987, 68:231-240.
23. Auclair S., Milenkovic D., Besson C., Chauvet S., Gueux E., Morand C., et al. Catechin reduces atherosclerotic lesion development in apo E-deficient mice: a transcriptomic study. Atherosclerosis 2009, 204:e21-e27.
24. le Morvan V., Dumon M.F., Palos-Pinto A., Berard A.M. n-3 FA increase liver uptake of HDL-cholesterol in mice. Lipids 2002, 37:767-772.
25. Benzie I.F., Strain J.J. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996, 239:70-76.
26. Nicoletti A., Kaveri S., Caligiuri G., Bariety J., Hansson G.K. Immunoglobulin treatment reduces atherosclerosis in apoE knockout mice. J Clin Invest 1998, 102:910-918.
27. Berard A.M., Foger B., Remaley A., Shamburek R., Vaisman B.L., Talley G., et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med 1997, 3:744-749.
28. Beissbarth T., Speed T.P. GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 2004, 20:1464-1465.
29. Maier J.A., Malpuech-Brugere C., Zimowska W., Rayssiguier Y., Mazur A. Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Acta 2004, 1689:13-21.
30. Potier M., Karl M., Elliot S.J., Striker G.E., Striker L.J. Response to sex hormones differs in atherosclerosis-susceptible and -resistant mice. Am J Physiol Endocrinol Metab 2003, 285:E1237-E1245.
31. Paigen B., Holmes P.A., Mitchell D., Albee D. Comparison of atherosclerotic lesions and HDL-lipid levels in male, female, and testosterone-treated female mice from strains C57BL/6, BALB/c, and C3H. Atherosclerosis 1987, 64:215-221.
32. Brett G.M., Hollands W., Needs P.W., Teucher B., Dainty J.R., Davis B.D., et al. Absorption, metabolism and excretion of flavanones from single portions of orange fruit and juice and effects of anthropometric variables and contraceptive pill use on flavanone excretion. Br J Nutr 2009, 101:664-675.
33. Bredsdorff L., Nielsen I.L., Rasmussen S.E., Cornett C., Barron D., Bouisset F., et al. Absorption, conjugation and excretion of the flavanones, naringenin and hesperetin from alpha-rhamnosidase-treated orange juice in human subjects. Br J Nutr 2010, 103:1602-1609.
34. Ishibashi S., Herz J., Maeda N., Goldstein J.L., Brown M.S. The 2-receptor model of lipoprotein clearance - tests of the hypothesis in knockout mice lacking the low-density-lipoprotein receptor, apolipoprotein-E, or both proteins. Proc Natl Acad Sci U S A 1994, 91:4431-4435.
35. Mahley R.W., Ji Z.S., Brecht W.J., Miranda R.D., He D. Role of heparan sulfate proteoglycans and the LDL receptor-related protein in remnant lipoprotein metabolism. Ann N Y Acad Sci 1994, 737:39-52.
36. Spertini O., Luscinskas F.W., Kansas G.S., Munro J.M., Griffin J.D., Gimbrone M.A., et al. Leukocyte adhesion molecule-1 (LAM-1, l-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion. J Immunol 1991, 147:2565-2573.
37. Pendu R., Terraube V., Christophe O.D., Gahmberg C.G., de Groot P.G., Lenting P.J., et al. P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood 2006, 108:3746-3752.
38. Barlic J., Murphy P.M. Chemokine regulation of atherosclerosis. J Leukoc Biol 2007, 82:226-236.
39. Hordijk P.L. Endothelial signalling events during leukocyte transmigration. FEBS J 2006, 273:4408-4415.
40. Carman C.V., Springer T.A. A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J Cell Biol 2004, 167:377-388.
41. Cho T., Jung Y., Koschinsky M.L. Apolipoprotein(a), through its strong lysine-binding site in KIV(19'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem 2008, 283:30503-30512.
42. Jacobson J.R., Dudek S.M., Birukov K.G., Ye S.Q., Grigoryev D.N., Girgis R.E., et al. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol 2004, 30:662-670.
43. Koss M., Pfeiffer G.R., Wang Y., Thomas S.T., Yerukhimovich M., Gaarde W.A., et al. Ezrin/radixin/moesin proteins are phosphorylated by TNF-alpha and modulate permeability increases in human pulmonary microvascular endothelial cells. J Immunol 2006, 176:1218-1227.
44. Schnoor M., Parkos C.A. Disassembly of endothelial and epithelial junctions during leukocyte transmigration. Front Biosci 2008, 13:6638-6652.
45. Broman M.T., Kouklis P., Gao X., Ramchandran R., Neamu R.F., Minshall R.D., et al. Cdc42 regulates adherens junction stability and endothelial permeability by inducing alpha-catenin interaction with the vascular endothelial cadherin complex. Circ Res 2006, 98:73-80.
46. Heasman S.J., Ridley A.J. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008, 9:690-701.
47. Kundumani-Sridharan V., Wang D., Karpurapu M., Liu Z., Zhang C., Dronadula N., et al. Suppression of activation of signal transducer and activator of transcription-5B signaling in the vessel wall reduces balloon injury-induced neointima formation. Am J Pathol 2007, 171:1381-1394.
48. Yoon J.J., Lee Y.J., Kim J.S., Kang D.G., Lee H.S. Betulinic acid inhibits high glucose-induced vascular smooth muscle cells proliferation and migration. J Cell Biochem 2010, 111:1501-1511.
49. Chen S., Gardner D.G. Suppression of WEE1 and stimulation of CDC25A correlates with endothelin-dependent proliferation of rat aortic smooth muscle cells. J Biol Chem 2004, 279:13755-13763.
50. Onda M., Naito Z., Wang R., Fujii T., Kawahara K., Ishiwata T., et al. Expression of keratinocyte growth factor receptor (KGFR/FGFR2 IIIb) in vascular smooth muscle cells. Pathol Int 2003, 53:127-132.